Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation.
暂无分享,去创建一个
Donatello Telesca | Roman Gulati | P. Nelson | Ruth Etzioni | K. Russell | D. Telesca | C. Higano | E. Yu | R. Gulati | Celestia S Higano | Evan Y Yu | Peter S Nelson | Peter Jiang | Stephen Tam | Kenneth J Russell | Ruth D Etzioni | P. Jiang | S. Tam
[1] Susan Halabi,et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] U. Steiner,et al. Randomised prospective study of intermittent versus continuous androgen suppression in advanced prostate cancer , 2007 .
[3] C. Tangen,et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] Paul Schellhammer,et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. , 2006, International journal of radiation oncology, biology, physics.
[5] H. Scher,et al. Time to Detectable Metastatic Disease in Patients with Rising Prostate-Specific Antigen Values following Surgery or Radiation Therapy , 2005, Clinical Cancer Research.
[6] L. Egevad,et al. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma , 2005, The American journal of surgical pathology.
[7] A W Partin,et al. Natural history of progression after PSA elevation following radical prostatectomy. , 1999, JAMA.
[8] L. Kaufman,et al. PSA evolution: a prognostic factor during treatment of advanced prostatic carcinoma with total androgen blockade. Data from a Belgian multicentric study of 546 patients. , 1997, Acta urologica Belgica.
[9] T. D. de Reijke,et al. Long-term efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate specific antigen normalization , 1997 .
[10] J. Fowler,et al. Prostate specific antigen regression and progression after androgen deprivation for localized and metastatic prostate cancer. , 1995, The Journal of urology.
[11] T. Peters,et al. Prostate-specific antigen and prognosis in patients with metastatic prostate cancer--a multivariable analysis of prostate cancer mortality. , 1995, British journal of urology.
[12] J. Miller,et al. The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer. , 1992, The Journal of urology.
[13] T. D. de Reijke,et al. Long-term efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate specific antigen normalization. International Anandron Study Group. , 1997, The Journal of urology.